Compugen Shares Slide 5.5 Percent on Faint Q4 | GenomeWeb
NEW YORK (GenomeWeb News) — Shares in Compugen slid 5.53 percent, or $.16, to $2.83 in mid-afternoon trading today after the company reported a 20-percent jump in R&D spending and a 12-percent jump in net loss atop weak revenue.
As GenomeWeb News reported this morning, Compugen also said it may need to raise additional cash by the middle of 2009 if it continues spending as it has been.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.